11 – 19 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2007
-
Mark
Expression pattern of JunD after acute or chronic l-DOPA treatment: Comparison with DeltaFosB.
(
- Contribution to journal › Article
-
Mark
Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
- 2006
-
Mark
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
(
- Contribution to journal › Article
- 2005
-
Mark
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
(
- Contribution to journal › Article
- 2004
-
Mark
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
(
- Contribution to journal › Article
- 2003
-
Mark
Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment.
(
- Contribution to journal › Article
-
Mark
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »